Richmond, VA, United States of America

Mohmed Elfatih Ashmaig

USPTO Granted Patents = 2 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Spotlight on Mohmed Elfatih Ashmaig

Introduction

Mohmed Elfatih Ashmaig is a prominent inventor based in Richmond, VA, known for his contributions to medical research and diagnostics. With two patents to his name, Ashmaig has made significant strides in the field of ultra-small apoB-containing particles, vital for advancing diagnostic methods.

Latest Patents

Ashmaig's latest patents include the development of ultra-small, lipid-depleted apoB-containing particles. These isolated particles are characterized by their very high density and potential for containing cytokeratin 8. The innovative aspect of these particles lies in their application in diagnostic assays, significantly enhancing the accuracy and efficiency of medical diagnostics. His work not only reflects deep scientific inquiry but also holds promise for improved health outcomes.

Career Highlights

Currently, Mohmed Elfatih Ashmaig is affiliated with the Children’s Hospital & Research Center at Oakland, where he continues to focus on groundbreaking innovations in diagnostics. His research is instrumental in developing new methodologies that can revolutionize current practices in the medical field.

Collaborations

In his work, Ashmaig collaborates with Ronald M. Krauss, a notable figure in the field. Their partnership is expected to yield progressive insights and advancements, particularly in medical applications of their research findings.

Conclusion

Mohmed Elfatih Ashmaig’s innovative work in the development of ultra-small apoB-containing particles exemplifies how inventors can significantly influence the science of diagnostics. As his research continues to evolve, the potential to improve diagnostic techniques remains high, marking him as an inventor to watch in the coming years.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…